A Multicentre, Comparative, Open-label, Randomized, Phase III Study to Assess the Immunogenicity and Safety of EutravacTMinj (DTaP-HB Combined Vaccine) Administered at 2, 4, 6 Months of Age Compared With DTaP Vaccine at 2, 4, 6 Months of Age Combined with Monovalent Hepatitis B Vaccine Administered at Birth, 1, 6 Months of Age in Healthy Infants.

Trial Profile

A Multicentre, Comparative, Open-label, Randomized, Phase III Study to Assess the Immunogenicity and Safety of EutravacTMinj (DTaP-HB Combined Vaccine) Administered at 2, 4, 6 Months of Age Compared With DTaP Vaccine at 2, 4, 6 Months of Age Combined with Monovalent Hepatitis B Vaccine Administered at Birth, 1, 6 Months of Age in Healthy Infants.

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Jul 2013

At a glance

  • Drugs DTaP-hepatitis B vaccine (Primary) ; DTaP vaccine; Hepatitis B vaccine
  • Indications Diphtheria; Hepatitis B; Pertussis; Tetanus
  • Focus Pharmacodynamics; Registrational
  • Most Recent Events

    • 20 Jul 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top